Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

MN Kosiborod, M Bhatta, M Davies… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …
被引用次数：42 相关文章

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

MN Kosiborod - 2022 - sciencehub.novonordisk.com
of the original article Fusce posuere, magna sed pulvinar ultricies, purus lectus commodo
magna eros quis urna. Page 1 © 2022 Novo Nordisk A/S; Further reproduction and …

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.

MN Kosiborod, M Bhatta, M Davies… - Diabetes, Obesity & …, 2022 - europepmc.org
Aims Evaluate the effects of once-weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …
[HTML] nih.gov

[HTML][HTML] Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

MN Kosiborod, M Bhatta, M Davies… - Diabetes, Obesity & …, 2023 - ncbi.nlm.nih.gov
Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.

MN Kosiborod, M Bhatta, M Davies… - Diabetes, Obesity & …, 2023 - search.ebscohost.com
Aims: Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

MN Kosiborod, M Bhatta, M Davies… - Diabetes, obesity & …, 2023 - pubmed.ncbi.nlm.nih.gov
Aims Evaluate the effects of once-weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

MN Kosiborod, M Bhatta, M Davies… - Diabetes, Obesity …, 2022 - discovery.ucl.ac.uk
Aims: Evaluate the effects of once-weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

MN Kosiborod, M Bhatta, M Davies… - Diabetes, Obesity …, 2023 - scholars.northwestern.edu
Aims: Evaluate the effects of once-weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.

MN Kosiborod, M Bhatta, M Davies, JE Deanfield… - 2022 - figshare.le.ac.uk
Evaluate the effects of semaglutide 2.4 mg on cardiometabolic risk factors in people with
overweight/obesity without diabetes in the STEP 1 and 4 trials. STEP 1 and 4 were phase III …
[PDF] scienceopen.com

[PDF][PDF] Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

MN Kosiborod, M Bhatta, M Davies, JE Deanfield… - …, 2022 - scienceopen.com
Aims: Evaluate the effects of once-weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …